PPY2P: A promising drug target and biomarker for pancreatic cancer

Target Name: PPY2P

NCBI ID: G23614

PPY2P

Other Name(s): Pancreatic polypeptide 2, pseudogene | PPY2 | pancreatic polypeptide 2, pseudogene

PPY2P: A promising drug target and biomarker for pancreatic cancer

Introduction

Pancreatic cancer is a highly aggressive and often lethal form of cancer, with a poor prognosis due to its late-stage presentation and limited treatment options. The development of new treatments and biomarkers for pancreatic cancer is crucial for improving survival and quality of life. One A promising candidate for drug targeting and biomarker is the pseudogene, Pancreatic Polypeptide 2 (PPY2P).

PPY2P is a 21-kDa protein that is expressed in various tissues, including pancreas, spleen, and blood. It is a member of the superfamily of secreted peptides and is characterized by its ability to induce cell proliferation and enhance tissue repair. The unique feature of PPY2P is its potential to participate in cell signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT signaling pathways.

In addition to its potential as a drug target, PPY2P has also been identified as a potential biomarker for pancreatic cancer. The increased expression of PPY2P has been observed in various pancreatic cancer cell lines and primary tissues, and it has been associated with poor prognosis in pancreatic cancer patients.

Drug targeting against PPY2P

The development of new treatments for pancreatic cancer is an ongoing effort to improve survival and quality of life. One of the promising approaches is the use of small molecules or antibodies to specifically target PPY2P and inhibit its activity.

One potential target for PPY2P is the serine/threonine protein kinase, FAK. FAK is a validated drug target for various diseases, including pancreatic cancer. It has been shown to be involved in cell signaling pathways, including the TGF-β pathway. By inhibiting FAK, researchers have observed a reduction in pancreatic cancer cell proliferation and increased cell death.

Another potential target for PPY2P is the protein tyrosine kinase, PDGFR. PDGFR is a member of the tyrosine kinase family and is involved in cell signaling pathways, including the PI3K/AKT signaling pathway. By inhibiting PDGFR, researchers have observed a reduction in pancreatic cancer cell proliferation and increased cell death.

Biomarkers for pancreatic cancer

PPY2P has also been identified as a potential biomarker for pancreatic cancer. The increased expression of PPY2P has been observed in various pancreatic cancer cell lines and primary tissues. In addition, studies have shown that PPY2P has been associated with poor prognosis in pancreatic cancer patients.

The role of PPY2P as a biomarker for pancreatic cancer has implications for the development of new diagnostic tests and therapeutic approaches. By identifying biomarkers for pancreatic cancer, researchers may be able to develop new treatments and improve survival for this aggressive form of cancer.

Conclusion

PPY2P is a promising candidate for drug targeting and biomarker in pancreatic cancer. Its unique feature as a member of the superfamily of secreted peptides and its potential involvement in cell signaling pathways make it an attractive target for small molecules and antibodies.

Further research is needed to fully understand the role of PPY2P as a biomarker for pancreatic cancer and its potential as a drug target. By developing new diagnostic tests and therapeutic approaches based on PPY2P, researchers may be able to improve survival and quality of life for pancreatic cancer cancer patients.

Protein Name: Pancreatic Polypeptide 2, Pseudogene

The "PPY2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPY2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets